In HPV16-positive oropharyngeal cancer, CD163+ DC3s support antitumor immunity by driving CD4+ and CD8+ type I responses and cytokine production, associated with tumor-specific T cell infiltration and improved patient survival [92]. Here, CD4 is linked to neoplasm.